Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7
|
pubmed:dateCreated |
1997-10-9
|
pubmed:abstractText |
To determine the characteristics of the N-terminal transactivation domain (AF-1) of the mouse estrogen receptor (ER), we constructed a number of deletion mutants. Wild-type and mutant receptors were expressed in yeast cells and assayed for their ability to transactivate an estrogen-responsive reporter plasmid (ERE-CYCl-LacZ) that contained a single estrogen response element of the vitellogenin A2 gene promoter. Deletion of the N-terminal 121 amino acids from the mouse ER resulted in a 50% reduction in transactivation activity compared with the full-length wild-type ER. Deletion of the first 150 amino acids resulted in loss of 90% transactivation activity. An ER deletion mutant lacking residues 121-154 retained full transcriptional activity, suggesting that this region plays a significant transacting role only when the first portion is deleted. A point mutation was introduced in the C-terminal region at Met-521 in order to study the possible interaction between the C-terminal ligand-binding domain and the N-terminal AF-1 region. This mutant ER, M521G, exhibited 150% of the transcriptional activity of the wild-type ER. An M521G mutant lacking the N-terminal 121 amino acids retained full transactivation activity, whereas, M521G lacking 150 amino acids resulted in only 10% of wild-type activity. These results suggest that residues 121-154 might interact with the C terminus to affect transcription. In summary, multiple N-terminal regions in the ER were identified that function in transactivation. Furthermore, a point mutation in the C-terminal portion of the ER may change the conformation of the ER ligand-binding domain, producing a more stable receptor/ligand complex that increases transcriptional activity. These data suggest that the N- and C-terminal portions of the ER interact in a cooperative manner to activate transcription from target genes.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0039-128X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
62
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
508-15
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:9253789-Animals,
pubmed-meshheading:9253789-Binding Sites,
pubmed-meshheading:9253789-Genes, Reporter,
pubmed-meshheading:9253789-Mice,
pubmed-meshheading:9253789-Models, Biological,
pubmed-meshheading:9253789-Mutation,
pubmed-meshheading:9253789-Point Mutation,
pubmed-meshheading:9253789-Receptors, Estrogen,
pubmed-meshheading:9253789-Recombinant Proteins,
pubmed-meshheading:9253789-Sequence Deletion,
pubmed-meshheading:9253789-Transcriptional Activation,
pubmed-meshheading:9253789-Vitellogenins,
pubmed-meshheading:9253789-Yeasts,
pubmed-meshheading:9253789-beta-Galactosidase
|
pubmed:year |
1997
|
pubmed:articleTitle |
Two transcription activation functions in the amino terminus of the mouse estrogen receptor that are affected by the carboxy terminus.
|
pubmed:affiliation |
Receptor Biology Section, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA.
|
pubmed:publicationType |
Journal Article
|